CClinicalTrials.gg
Enrolling by invitationNCT02473757Updated Aug 31, 2026

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

An observational study in Lyphoma, B-Cell, Leukemia, B-cell and Multiple Myeloma, sponsored by National Cancer Institute (NCI). Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by National Cancer Institute (NCI) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

Background:

- Gene therapy is a way to treat or prevent disease using genes. It is monitored very closely by regulators because there can be long-term, unexpected side effects. NIH is required to try to contact people who have been treated with gene therapy at least annually for up to 15 years. This is to see if they have had any bad side effects. This trial does not include any therapy and is only for patients previously treated on gene-therapy trials at the NCI Surgery Branch who are no longer enrolled on their original gene therapy clinical trial.

Objective:

- To collect of long-term follow-up data on people who have been in gene transfer studies. This follow-up is required by regulators.

Eligibility:

- People age 18 and older who have been in a previous NCI Surgery Branch gene therapy research study.

Design:

  • After they get the genetically modified cells, participants will:
  • Have blood drawn 3, 6, and 12 months later.
  • Have an annual clinic visit for the next 4 years. They will have a physical exam. They will answer questions about any signs of neurological, autoimmune, or blood disorders, or any new cancers. Blood may be drawn.
  • Be called or emailed annually for the next 10 years. They will answer health questions. Blood samples may need to be taken.
  • Participants will be asked for their current address and phone number. They will also be asked for the address and phone number of 1 or 2 people who will know their whereabouts. One of these should be a family member if possible,
  • At the time of the participant s death, researchers will request permission from their family for an autopsy.
Read the detailed description

Background:

-The National Cancer Institute Surgery Branch (NCI-SB) Branch investigator conducts clinical trials utilizing gene transfer. The current U.S. Food and Drug Administration (FDA) requirements for long term follow up may be up to fifteen years for some products. As this time period is frequently longer than studies are expected to be open, a long-term follow-up protocol is necessary to ensure the follow up of these subjects

Objectives:

-To facilitate collection of long term, follow up information on subjects who have participated in gene transfer studies as required by the U.S. Food and Drug Administration and other regulatory groups

Eligibility:

-Enrollment on a CAR T-cell treatment protocol for gene therapy.

Design:

-Patients will undergo physical exams; laboratory evaluation or phone follow up as required by the treatment protocol and/or as clinically indicated.

02

Conditions studied

  • Lyphoma, B-Cell
  • Leukemia, B-cell
  • Multiple Myeloma
  • Hematologic Malignancies

Keywords

  • Recombinant DNA Product
  • Laboratory Evaluation
  • NIH Office of Biotechnology Activities
  • Gamma-Retroviral Vectors
  • Natural History
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

To facilitate collection of long term follow up information on subjects who have participated in gene transfer studies as required by the U.S. Food and Drug Administration and other regulatory groups

Eligibility criteria

  • INCLUSION CRITERIA:
  • Subjects who have received treatment on a CAR T-cell gene therapy protocol. Age >= 18 years as children are generally excluded from CAR T-cell gene therapy studies.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)

Groups and cohorts

  • 1/Cohort 1

    Subjects who have received treatment on an NCI Surgery Branch CAR T-cell gene therapy protocols.

05

What researchers measure

Primary outcomes

  1. To provide long term follow up of patients previously enrolled on treatment protocols in the NCI ETIB Branch.

    List of long time adverse event frequency after Gene therapy drug

    Time frame: 15 years

06

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
07

References and documents

08

Registry details

Key details

Study ID
NCT02473757
Lead sponsor
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Jun 17, 2015
Start date
Sep 24, 2015
Primary completion
Jul 1, 2034 (estimated)
Completion
Aug 1, 2050 (estimated)
Last update
Aug 31, 2026

Study contacts

James N Kochenderfer, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion